Featured Company News - Moleculin Biotech Acquires Active Drug Compound for the Treatment of Brain Cancer
Research Desk Line-up: Tesaro Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 18, 2017 /Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Moleculin Biotech, Inc. (NASDAQ: MBRX), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MBRX. The Company announced on August 16, 2017, that it has acquired WP122, an active drug compound that it plans to study for the treatment of brain tumors. Moleculin has secured exclusive access to a significant quantity of GMP synthesized WP1122 drug substance from its sublicense partner in Poland. Moleculin Biotech is a preclinical stage pharmaceutical Company focused on the development of anti-cancer drugs, some of which are made at MD Anderson Cancer Center. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Tesaro, Inc. (NASDAQ: TSRO) for due-diligence and potential coverage as the Company reported on August 08, 2017, its operating results for Q2 2017 and also provided an update on its commercial products and development programs. Tune in to our site to register for a free membership, and be among the early birds that get our report on Tesaro when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MBRX; also brushing on TSRO. Go directly to your stock of interest and access today's free coverage at:
The Company made this announcement following the realization of potential of WP1122 technology, and its ability to be a new approach for treating brain tumors. Moleculin Biotech announced that access to this product would enable it to accelerate preclinical toxicology and analytical testing of WP1122, which enables preparation of an Investigational New Drug application so that it could begin proof of concept clinical trials.
The Company stated that the research at MD Anderson using live human brain tumors transplanted into mice has shown that WP1122 has the potential to outperform the current standard of care treatment for glioblastoma, one of the most pervasive forms of brain tumors. Moleculin Biotech expects to get this drug into human testing to determine if there is something which could make a real difference for patients.
Moleculin Biotech's lead product candidate is Annamycin, an anthracycline being studied for treatment of relapsed or refractory acute myeloid leukemia (AML). The Company also has two preclinical small molecule portfolio where one is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system, while the other portfolio targets the metabolism of tumors.
On July 18, 2017, the Company announced a new technology license agreement with MDA Cancer Center based on new patent applications the Company intends to file relating to its drug Annamycin for the treatment of relapsed or refractory AML. Post the announcement, on August 09, 2017, Moleculin Biotech announced that it has received recent FDA approvals for new drugs for the treatment of AML. According to the Company, the recent approval of three new drugs - Rydapt, Vyxeos, and Idhifa - for the treatment of AML offer additional options in terms of treatments in defined subpopulations.
With respect to AML, Rydapt is approved only for patients with a specific gene mutation and for use in combination with the standard of care chemotherapy. Vyxeos is approved as an option to the standard of care, but only for specific AML patients. Jazz Pharmaceuticals purchased Vyxeos in a $1.5 billion acquisition of Celator Pharmaceuticals. Also, on August 03, 2017, the Company appointed BioScience SA, a Polish contract research organization to begin identifying and preparing clinical testing sites in Poland for its drug Annamycin for the treatment of relapsed or refractory AML.
Last Close Stock Review
On Thursday, August 17, 2017, the stock closed the trading session at $2.56, slipping 3.40% from its previous closing price of $2.65. A total volume of 274.78 thousand shares have exchanged hands. Moleculin Biotech's stock price skyrocketed 36.90% in the last one month, 239.07% in the past three months, and 111.57% in the previous six months. Furthermore, since the start of the year, shares of the Company have surged 12.28%. The stock currently has a market cap of $48.28 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
© 2017 Accesswire. All Rights Reserved.